Fundz

Who to call at Hanmi Pharmaceutical Ltd, and when

Fundz watches for the moments Hanmi Pharmaceutical Ltd starts buying, and tells you who to reach.

  • An alert the day Hanmi Pharmaceutical Ltd raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Hanmi Pharmaceutical Ltd, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Hanmi Pharmaceutical Ltd. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Hanmi Pharm Licenses Oral Drug Delivery Platform to Gilead for Encequidar Development.

Sep 29, 2025

Contract Type

agreement

South KoreaBiotechnologyHealth CarePharmaceuticalpharmaceuticals

Description

Hanmi Pharm has entered into a global licensing and collaboration agreement with Gilead Sciences and Health Hope Pharma, granting Gilead exclusive rights to develop and commercialize Encequidar. The agreement includes upfront payments and potential royalties, with both companies collaborating on drug supply and technical know-how.

Company Information

Company

Hanmi Pharmaceutical Ltd

Location

South Korea

About

Hanmi Pharmaceutical Co. Ltd. is a biopharmaceutical company engaged in the research, development, manufacture, and marketing of innovative medicines with a focus on metabolic disorders, oncology, and rare diseases. With several partnerships and a global presence, Hanmi aims to enhance healthcare through cutting-edge therapies. The company is noted for its investment in research and development and has a strong pipeline of products.

Related People

Chulhyun
Senior decision-maker at this company
••••••••@••••••••

See Chulhyun's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Hanmi Pharmaceutical Ltd's next move

Learn about Strategic plan

Hanmi Pharmaceutical Ltd signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.